Top

Published in:

01-05-2020 | Dementia | Original Communication

Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Authors: Saul Martinez-Horta, Andrea Horta-Barba, Jesús Perez-Perez, Frederic Sampedro, Natascia de Lucia, Giuseppe De Michele, Stefanie Kehrer, Josef Priller, Simone Migliore, Ferdinando Squitieri, Anna Castaldo, Caterina Mariotti, Veronica Mañanes, Jose Luis Lopez-Sendon, Noelia Rodriguez, Asunción Martinez-Descals, Pedro Garcia-Ruiz, Filipa Júlio, Cristina Januário, Marianna Delussi, Marina de Tommaso, Sandra Noguera, Jesus Ruiz-Idiago, Emilia J. Sitek, Angela Nuzzi, Javier Pagonabarraga, Jaime Kulisevsky, Cognitive Phenotype Working Group of the European Huntington’s Disease Network

Published in: Journal of Neurology | Issue 5/2020

Abstract

Background

Cognitive impairment is an essential feature of Huntington’s disease (HD) and dementia is a predictable outcome in all patients. However, validated instruments to assess global cognitive performance in the field of HD are lacking.

Objectives

We aimed to explore the utility of the Parkinson’s disease-Cognitive Rating Scale (PD-CRS) for the screening of global cognition in HD.

Methods

A multicenter cohort of 132 HD patients at different disease stages and 33 matched healthy controls were classified as having preserved cognition, mild cognitive impairment (HD-MCI) or dementia (HD-Dem) according to the Clinical Dementia Rating and Functional Independence Score. The PD-CRS and the Mini-Mental State Examination were administered. Receiver operating characteristic curve analysis was used to determine optimal cutoffs to differentiate patients according to their cognitive status.

Results

A PD-CRS cutoff score ≤ 81/82 was optimal to detect HD-MCI (sensitivity = 93%; specificity = 80%; area under the curve (AUC) = 0.940), and ≤ 63/64 was optimal to detect HD-Dem (sensitivity = 90%; specificity = 87%; AUC = 0.933). MMSE scores failed to show robust psychometric properties in this context.

Discussion

The PD-CRS is a valid and reliable instrument to assess global cognition in HD in routine clinical care and clinical trials.

Available only for authorised users

Walker FO (2007) Huntington's disease. Lancet 369(9557):218–228. https://doi.org/10.1016/S0140-6736(07)60111-1CrossRefPubMed

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204–216. https://doi.org/10.1038/nrneurol.2014.24CrossRefPubMed

Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69–91. https://doi.org/10.1016/B978-0-12-801893-4.00006-7CrossRefPubMed

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791–801. https://doi.org/10.1016/S1474-4422(09)70170-XCrossRefPubMedPubMedCentral

Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J (2010) Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 25(9):1163–1169. https://doi.org/10.1002/mds.22953CrossRefPubMedPubMedCentral

Dogan I, Eickhoff SB, Schulz JB, Shah NJ, Laird AR, Fox PT, Reetz K (2013) Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis. Neuro-degener Dis 12(1):23–35. https://doi.org/10.1159/000339528CrossRef

Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65(5):745–747. https://doi.org/10.1212/01.wnl.0000174432.87383.87CrossRefPubMed

Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS (2010) Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40(3):544–554. https://doi.org/10.1016/j.nbd.2010.07.014CrossRefPubMedPubMedCentral

Sampedro F, Martinez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernandez-Leon A, Gomez-Anson B, Carrio I, Kulisevsky J (2019) Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. Eur J Nucl Med Mol Imaging 46(5):1111–1116. https://doi.org/10.1007/s00259-018-4257-zCrossRefPubMed

10.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M (2018) Natural biological variation of white matter microstructure is accentuated in Huntington's disease. Hum Brain Mapp. https://doi.org/10.1002/hbm.24191CrossRefPubMedPubMedCentral

11.

Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. https://doi.org/10.3389/fnagi.2014.00078CrossRefPubMedPubMedCentral

12.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR (2012) Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42–53. https://doi.org/10.1016/S1474-4422(11)70263-0CrossRefPubMed

13.

Mestre TA, Bachoud-Levi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P (2018) Rating scales for cognition in Huntington's disease: critique and recommendations. Mov Disord 33(2):187–195. https://doi.org/10.1002/mds.27227CrossRefPubMed

14.

Julayanont P, McFarland NR, Heilman KM (2020) Mild cognitive impairment and dementia in motor manifest Huntington's disease: classification and prevalence. J Neurol Sci 408:116523. https://doi.org/10.1016/j.jns.2019.116523CrossRefPubMed

15.

Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6):500–507. https://doi.org/10.1212/WNL.0b013e3181eccfa2CrossRefPubMedPubMedCentral

16.

Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM (2010) The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord 25(3):401–404. https://doi.org/10.1002/mds.22748CrossRefPubMed

17.

Ringkobing SP, Larsen IU, Jorgensen K, Vinther-Jensen T, Vogel A (2019) Cognitive screening tests in huntington gene mutation carriers: examining the validity of the mini-mental state examination and the montreal cognitive assessment. J Huntington's Dis. https://doi.org/10.3233/JHD-190350CrossRef

18.

Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A (2008) Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 23(7):998–1005. https://doi.org/10.1002/mds.22007CrossRefPubMed

19.

Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J (2013) Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 28(10):1376–1383. https://doi.org/10.1002/mds.25568CrossRefPubMed

20.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969. https://doi.org/10.1093/brain/awp245CrossRefPubMed

21.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P (2018) Global scales for cognitive screening in Parkinson's disease: critique and recommendations. Mov Disord 33(2):208–218. https://doi.org/10.1002/mds.27233CrossRefPubMed

22.

Group HS (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142. https://doi.org/10.1002/mds.870110204CrossRef

23.

Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1–3. https://doi.org/10.1212/wnl.29.1.1CrossRefPubMed

24.

Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41(5):689–692. https://doi.org/10.1002/ana.410410521CrossRefPubMed

25.

Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572CrossRef

26.

Callaghan J, Stopford C, Arran N, Boisse MF, Coleman A, Santos RD, Dumas EM, Hart EP, Justo D, Owen G, Read J, Say MJ, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Bachoud-Levi AC, Bourdet C, van Duijn E, Craufurd D (2015) Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci 27(1):59–64. https://doi.org/10.1176/appi.neuropsych.13070169CrossRefPubMed

27.

Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013) The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease. J Neurol 260(11):2777–2785. https://doi.org/10.1007/s00415-013-7061-5CrossRefPubMed

28.

Stout JC, Queller S, Baker KN, Cowlishaw S, Sampaio C, Fitzer-Attas C, Borowsky B (2014) HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3. Mov Disord 29(10):1281–1288. https://doi.org/10.1002/mds.25964CrossRefPubMed

29.

Mickes L, Jacobson M, Peavy G, Wixted JT, Lessig S, Goldstein JL, Corey-Bloom J (2010) A comparison of two brief screening measures of cognitive impairment in Huntington's disease. Mov Disord 25(13):2229–2233. https://doi.org/10.1002/mds.23181CrossRefPubMed

30.

Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC (2018) Structural and functional changes of the visual cortex in early Huntington's disease. Hum Brain Mapp 39(12):4776–4786. https://doi.org/10.1002/hbm.24322CrossRefPubMedPubMedCentral

31.

Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI (2015) The impact of occipital lobe cortical thickness on cognitive task performance: an investigation in Huntington's Disease. Neuropsychologia 79(Pt A):138–146. https://doi.org/10.1016/j.neuropsychologia.2015.10.033CrossRefPubMed

32.

Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O'Regan A, Queller S, Frost C, Leavitt BR, Durr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC (2016) Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington's disease. J Int Neuropsychol Soc 22(6):595–608. https://doi.org/10.1017/S1355617716000321CrossRefPubMed

Title: Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease
Authors: Saul Martinez-Horta
Andrea Horta-Barba
Jesús Perez-Perez
Frederic Sampedro
Natascia de Lucia
Giuseppe De Michele
Stefanie Kehrer
Josef Priller
Simone Migliore
Ferdinando Squitieri
Anna Castaldo
Caterina Mariotti
Veronica Mañanes
Jose Luis Lopez-Sendon
Noelia Rodriguez
Asunción Martinez-Descals
Pedro Garcia-Ruiz
Filipa Júlio
Cristina Januário
Marianna Delussi
Marina de Tommaso
Sandra Noguera
Jesus Ruiz-Idiago
Emilia J. Sitek
Angela Nuzzi
Javier Pagonabarraga
Jaime Kulisevsky
Cognitive Phenotype Working Group of the European Huntington’s Disease Network
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Dementia
Parkinson's Disease
Dementia
Huntington's Disease
Mild Cognitive Impairment
Published in: Journal of Neurology / Issue 5/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09730-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Abstract

Background

Objectives

Methods

Results

Discussion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 5/2020

Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria

Pre-treatment cerebral microbleeds and intracranial hemorrhage in patients with ischemic stroke receiving endovascular therapy: a systematic review and meta-analysis

White matter and cerebellar involvement in alternating hemiplegia of childhood

ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage

Functional disconnection of the dentate nucleus in essential tremor

Magnetic resonance imaging in immune-mediated myelopathies